Center for Molecular Imaging, Departments of Radiation Oncology and, and Radiology, University of Michigan, Ann Arbor, Michigan 48109, United States.
Mol Pharm. 2010 Dec 6;7(6):1921-9. doi: 10.1021/mp100298r. Epub 2010 Oct 27.
The past decade has seen momentous development in brain cancer research in terms of novel imaging-assisted surgeries, molecularly targeted drug-based treatment regimens or adjuvant therapies and in our understanding of molecular footprints of initiation and progression of malignancy. However, mortality due to brain cancer has essentially remained unchanged in the last three decades. Thus, paradigm-changing diagnostic and therapeutic reagents are urgently needed. Nanotheranostic platforms are powerful tools for imaging and treatment of cancer. Multifunctionality of these nanovehicles offers a number of advantages over conventional agents. These include targeting to a diseased site thereby minimizing systemic toxicity, the ability to solubilize hydrophobic or labile drugs leading to improved pharmacokinetics and their potential to image, treat and predict therapeutic response. In this article, we will discuss the application of newer theranostic nanoparticles in targeted brain cancer imaging and treatment.
过去十年,在新型影像辅助手术、分子靶向药物治疗方案或辅助治疗以及对癌症发生和发展的分子特征的理解方面,脑癌研究取得了重大进展。然而,在过去的三十年中,脑癌的死亡率基本保持不变。因此,迫切需要改变模式的诊断和治疗试剂。纳米诊疗平台是癌症成像和治疗的有力工具。与传统药物相比,这些纳米载体的多功能性具有许多优势。这些优势包括靶向疾病部位,从而最大限度地减少全身毒性,溶解疏水性或不稳定性药物的能力,从而改善药代动力学,以及它们在成像、治疗和预测治疗反应方面的潜力。本文将讨论新型治疗性纳米颗粒在靶向脑癌成像和治疗中的应用。